HER2 over-expression and response to different chemotherapy regimens in breast cancer.
- Author:
Jin ZHANG
1
;
Yan LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; administration & dosage; therapeutic use; Breast Neoplasms; chemistry; drug therapy; mortality; Cyclophosphamide; administration & dosage; Epirubicin; administration & dosage; Female; Fluorouracil; administration & dosage; Humans; Methotrexate; administration & dosage; Middle Aged; Receptor, ErbB-2; analysis
- From: Journal of Zhejiang University. Science. B 2008;9(1):5-9
- CountryChina
- Language:English
-
Abstract:
PURPOSETo exam the relationship between HER2 over-expression and different adjuvant chemotherapies in breast cancer.
PATIENTS AND METHODSA total of 1625 primary breast cancer patients who received post-surgery adjuvant chemotherapy in Tianjin Cancer Hospital, China, from July 2002 to November 2005 were included in the study. Among them, 600 patients were given CMF (CTX+MTX+5-Fu) regimen, 600 given CEF (CTX+E-ADM+5-Fu) regimen, and 425 given anthracyclines plus taxanes regimen, with mean follow-up time of 42 months.
RESULTSIn CMF treatment group, the 3-year disease free survival (DFS) in HER2 over-expressed patients was lower than that of the HER2-negative ones (89.80% vs 91.24%, P=0.0348); in node-positive subgroup, the 3-year DFS was 84.72% in HER2 over-expressed patients, and 90.18% in the HER-2-negative ones (P=0.0271). Compared to CMF regimen, anthracyclines and anthracyclines plus taxanes regimens are more effective (P<0.05) in node-positive HER2 over-expression than those in the node-negative.
CONCLUSIONHER2 over-expression is an independent index for predicting poor prognosis and short DFS for breast cancer patients. HER2 over-expressed patients are resistant to CMF regimen chemotherapy, but sensitive to anthracyclines-based or anthracyclines plus taxanes regimen. HER2 expression can be taken as a marker for therapies in breast cancer.
